WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > BRDG Park
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Medical, Industry Outlook
PRNewswire | June 19, 2023
"We care for your samples, you care for science" – Singleron holds true to their slogan as reliable partner to scientists and clinicians. Developing single cell multi-omics products that can be used in research and clinical settings, the launch of two new instruments extends their current portfolio that delivers one-stop-shop solutions for the single cell sequencing workflow. Scientists and clinical researchers appreciate the prospect of portable instruments that...
Businesswire | August 02, 2023
Replimune Group, Inc. a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte a global biopharmaceutical company, today announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor. “We are excited to enter into this collaboration with Incyte to explo...
Cell and Gene Therapy, Industrial Impact
Oxford Nanopore Technologies | February 17, 2023
On February 16, 2023, Oxford Nanopore Technologies announced that it will be furthering its collaboration with UPS Healthcare to expedite the distribution of its Oxford Nanopore DNA/RNA sequencing products and consumables throughout the Asia Pacific region. The collaborative effort will strengthen the supply chain for Oxford Nanopore's portable, real-time DNA sequencing devices in key markets across Asia. By leveraging the specialized healthcare logistics solutions provided ...
Industrial Impact
SIGA Technologies Inc. | July 16, 2022
SIGA Technologies, Inc. a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics to make TPOXX® available for use with KaliVir’s proprietary oncolytic vaccinia immunotherapy platform. This novel oncolytic platform includes multiple proprietary genetic modifications that can be combined to generate a unique oncolytic virus that has been optimized for systemic delivery and anti-tumor immune stimulatio...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE